Start/SYK

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze SYK in workspace
SYKNYSE/health care

Stryker Corporation

$331.45Up+1,67 (+0,51%)
Research reviewed: 12. Juli 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Stryker Corporation operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Eröffnung
330,18
Hoch
335,96
Tief
329,10
Marktkapitalisierung
127,06 Mrd.
KGV
38.36
52-Wochen-Hoch
--
Dividende
1.070%
Quartalsdividende
--

3-month price context

Das Chart zeigt den jüngsten 3-Monats-Trend, damit Nutzer die kurzfristige Struktur verstehen können, bevor sie den vollen Workspace öffnen.

Investment thesis

Base case
Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption. The base case remains conditional on supply and manufacturing staying manageable.
Bull case
Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption. Healthy elective procedure volumes can sustain demand across hips, knees, trauma and surgical equipment. New implants, neurovascular tools and operating-room technologies can extend share gains.
Bear case
Component shortages, quality issues or sterilization constraints could disrupt high-demand product availability. Budget pressure can delay purchases of robots, beds and other capital equipment. Frequent portfolio additions can raise integration, valuation and management-attention risk.

Key catalysts

  • Mako installed base

    Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption.

  • Procedure growth

    Healthy elective procedure volumes can sustain demand across hips, knees, trauma and surgical equipment.

  • Product innovation

    New implants, neurovascular tools and operating-room technologies can extend share gains.

Principal risks

  • Supply and manufacturing

    Component shortages, quality issues or sterilization constraints could disrupt high-demand product availability.

  • Hospital capital budgets

    Budget pressure can delay purchases of robots, beds and other capital equipment.

  • Acquisition execution

    Frequent portfolio additions can raise integration, valuation and management-attention risk.

Latest earnings research

Q1 2026

Stryker's first-quarter 2026 results reflected continued demand across MedSurg, Neurotechnology and Orthopaedics, supported by procedure volumes, capital equipment and product innovation.

Valuation interpretation

  • The installed-base model supports premium quality when robotic placements translate into recurring implant and service pull-through.
  • Procedure resilience should be assessed alongside hospital capital cycles and ongoing acquisition requirements.

Peer research

ABTBSXISRG

Recent news

Zacks · vor 3 Tagen

ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?

Simply Wall St. · vor 4 Tagen

Stryker (SYK) Stock Loses Russell Growth Slots As Active Investors Step In

Barchart · vor 4 Tagen

Stryker's Quarterly Earnings Preview: What You Need to Know

Insider Monkey · vor 4 Tagen

Mixed Drivers Fuel Optimism in Stryker Corporation’s (SYK) Performance

Trefis · vor 5 Tagen

The Wide Chasm Priced Into Boston Scientific Stock

Continue in the research workspace

Keep SYK in context, run a multi-agent analysis, and monitor thesis changes.

Analyze SYK free

Das gesamte Research-System erkunden

Jede Phase erfüllt eine klare Aufgabe und hinterlässt ein prüfbares Ergebnis.

AnalysemethodikMarktberichte lesen
Thesis invalidation
Reassess the thesis if component shortages, quality issues or sterilization constraints could disrupt high-demand product availability.

Trefis · vor 5 Tagen

Just How Much Risk Is Built Into ISRG Stock?

Data and research sources

Research updated: 12. Juli 2026, 00:00 UTC
3 verified sources
First Quarter 2026 Operating ResultsStryker Corporation · earningsVerified

Fetched: 12.7.2026, 0:00:00 UTC

Published: 30.4.2026, 00:00:00

Open original source
Stryker Corporation Investor RelationsStryker Corporation · companyVerified

Fetched: 12.7.2026, 0:00:00 UTC

Open original source
Stryker SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12.7.2026, 0:00:00 UTC

Published: 30.4.2026, 00:00:00

Open original source
Aktien erkunden

Continue researching this stock

Marktanalyst

Marktanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Fundamentalanalyst

Fundamentalanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Nachrichtenanalyst

Nachrichtenanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Risikomanager

Risikomanager fokussiert sich innerhalb von Risiko und Monitoring auf die Phase Überwachen und bereitet den Kontext für nachgelagerte Rollen vor.